Acclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies.

Acclaro Medical是一家开创性的医疗技术公司，专注于开发改善患者护理和重新定义医疗实践的前沿解决方案，欣然宣布其B轮融资成功结束。本轮融资由Accelmed Partners领投，现有投资者3E Bioventures Capital参投，总计2300万美元的资金标志着公司在通过创新的2910纳米光纤激光解决方案及其他颠覆性技术满足未被满足的美学需求的旅程中达到了一个关键里程碑。

This capital infusion will help Acclaro accelerate the growth of its flagship products, UltraClear® and AuraLux™ and expedite global market expansion while advancing development of new trailblazing products in its pipeline..

这笔资金的注入将有助于Acclaro加速其旗舰产品UltraClear®和AuraLux™的增长，加快全球市场扩张，并推动其研发管道中新的开创性产品的开发。

Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today's unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry.

Acclaro Medical 由世界级的行业专家创立于2018年，致力于开发、创新并推出革命性的解决方案，以满足当今未被满足的医疗、美容和外科实践需求。凭借对创新的不懈追求和一支专注的专业团队，Acclaro Medical 持续突破界限，推动美容医疗行业的积极变革。

Its proprietary 3DMIRACL™ and Laser Coring™ skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types..

其专有的3DMIRACL™和Laser Coring™皮肤再生治疗因其无与伦比的美学效果而备受推崇，同时兼具高患者舒适度、快速愈合和所有皮肤类型的最大安全性。